Improving early detection of liver cancer using advanced ultrasound techniques
Quantitative Ultrasound to Improve Detection and Diagnosis of Liver Cancer
This study is testing new ultrasound techniques to see if they can help doctors find liver cancer earlier in adults who are already being checked for it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 328 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT06345508 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the early detection of hepatocellular carcinoma (HCC) by utilizing innovative quantitative ultrasound (QUS) techniques. The research will compare the effectiveness of conventional B-mode ultrasound with advanced QUS methods, including shear wave viscoelastography and sub-resolution cellular imaging, in identifying liver nodules. The study will involve adult patients undergoing routine ultrasound or MRI surveillance for liver cancer, with MRI serving as the reference standard for diagnosis. By improving detection rates, the study seeks to facilitate earlier treatment and improve survival outcomes for patients with liver cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients scheduled for ultrasound or MRI surveillance of hepatocellular carcinoma or those undergoing MRI for liver nodule characterization.
Not a fit: Patients who have previously received locoregional or systemic therapy for liver cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the early detection of liver cancer, leading to better treatment options and improved survival rates for patients.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques for cancer detection, suggesting that this approach may yield beneficial results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Adult patients scheduled for US- or MRI-based surveillance of HCC or undergoing MRI-based imaging for characterization of liver nodules as part of their clinical standard of care. Exclusion Criteria: \- Patients with prior locoregional or systemic therapy.
Where this trial is running
Montreal, Quebec
- Centre Hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec, Canada (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.